Objectives: A drug delivery system based on colloidal pegylated gold nanoparticles (PEGAuNPs) conjugated with the tyrosine kinase inhibitor afatinib was designed and tested for enhancing the drug activity against pancreatic and non-small cell lung cancer cells. Methods: PEGAuNPs were synthesized and characterized physicochemically. Confocal imaging was performed to evaluate the nanoparticle internalization in cancer cells. For cell cycle distribution analysis, conjugated nanoparticles and afatinib alone were incubated with cells and alterations on the cell cycle profile subsequently analyzed by total DNA staining. Cancer cell survival and growth inhibition following incubation with afatinib and PEGAuNPs-afatinib (concentrations between 0.007 and 0.500 µM afatinib) were evaluated. Results: A higher cellular uptake of PEGAuNPs was observed by cancer cells. Our data suggest an efficient conjugation of PEGAuNPs with the drug, enhancing the afatinib activity in comparison with afatinib alone. In fact, IC50 and GI50 results obtained show that the PEGAuNPs-afatinib conjugate is ca. 5 and 20 times more potent than afatinib alone in S2-013 and A549 cell lines, respectively. Conclusions: Conjugating PEGAuNPs with afatinib is a promising antitumour delivery system for cancer therapy as it improves drug efficacy, allowing to decrease the dose of drug used and minimizing possible toxicity related side effects.
Introduction
Nanoparticles (NPs) have been considered an elective vector for targeted therapies, with expanding applications in medical nanotechnology [1] [2] [3] [4] . They are able to cross biological barriers and enter the cells, driven by the enhanced permeability and retention (EPR) of NPs in the tumour [5, 6] . Several studies revealed the influence of NPs physico-chemical characteristics and cell cycle phase on internalization process [7, 8] . Using a nanoparticle vector' inherent surface chemistry, a combination of targeting, imaging, therapeutic applications and, even photothermal or radiosensitizing therapies can be involved [8] .
Currently, gold nanoparticles (AuNPs) have been presented as drug-loaded nanocarriers, which remains one of the most promising drug delivery systems (DDS) to be used for cancer therapies and diagnosis [9] [10] [11] [12] . AuNPs have unusual and distinguish properties, being biocompatible and able to be coated with biocompatible polymers conferring them adequate surface charge, and stability [13] [14] [15] . The coupling of anticancer drugs to colloidal gold nanoparticles is a possible strategy once it is very important to ensure the activity of the drugs and the viability of the nanosystem (linkage stability) [16] . AuNPs can protect and decrease the antitumour drug dose to be administered to cancer patients (whilst increasing the drug dose being delivered into cancer cells), hence diminishing possible chemotherapy side effects [17] .
Several studies investigating AuNPs related toxicity in cancer cells, have reported that they do not present significant toxicity [15, [18] [19] [20] . Also, studies have shown that AuNPs are internalized by endocytosis process [8, 21, 22] . AuNPs present small sizes and are able to penetrate and accumulate at tumour sites through EPR effect [8] . They can improve the drug ability for tumour penetration and overcome the multidrug resistance (MDR) problem of solid tumours [23] .
is an aniline-quinazoline that irreversibly binds to the intracellular tyrosine kinase domain of the ErbB family of receptors (acting as a pan-ErbB inhibitor) [24] [25] [26] .
Upon binding to ErbB, afatinib blocks the signaling from homo and heterodimers inhibiting cell growth and inducing apoptosis in cancer cells. Afatinib is one of the agents approved for the treatment of non-small cell lung cancer (NSCLC) due to its antitumour effect [27, 28] . Indeed, afatinib has been approved for first-line treatment of patients with metastatic NSCLC, whose tumours have specific mutations in EGFR, namely exon 19 deletions or exon 21 (L858R) substitutions [29] . Some reports also suggest that afatinib can be a promising inhibitor against human pancreatic tumour cells [24, 30, 31] . Positive results have also been reported in the therapy of other advanced solid tumours, when afatinib is given in combination with conventional chemotherapeutic agents [26, 32] . In this study, we assessed in vitro the effect of afatinib conjugated with PEGAuNPs in pancreatic cancer cells (cell line S2-013), and NSCLC cells (cell line A549). Our aim is to enhance the effect of afatinib on cancer cells using PEGAuNPs. The nanoparticle system designed was characterized regarding particle size, stability, drug release and cytotoxicity. Our results reinforce that afatinib uptake and cell toxicity in pancreatic and lung cancer cells can be enhanced by conjugating afatinib with PEGAuNPs. Tricloroacetic acid (TCA) and Tris buffer were acquired from Merck (Darmstadt, Germany). a-thiol-wcarboxyl (polyethylene glycol) (HS-PEG-COOH; molecular weight 394.57 Da) was purchased from Prochimia (Poland).
Materials and methods

Chemicals
Cell lines
The pancreatic cell lines, S2-013 (well differentiated tubular adenocarcinoma and moderately metastatic subline cloned from the human pancreatic tumor cell line SUIT-2) was kindly provided by Prof. M. A.
Hollingsworth (Eppley Institute for Research in Cancer and Allied Diseases, UNMC, Omaha, NE, USA).
Adherent cell cultures were maintained in DMEM with 10% heat-inactivated FBS at 37 ºC in a humidified atmosphere of 5% CO2 incubator.
The non-small cell lung cancer cell line (A549) was a kind gift from Dr George DD Jones (University of Leicester, UK). A549 cells were grown as a monolayer in RPMI 1640 media with 10% heat-inactivated FBS at 37 ºC in a humidified atmosphere of 5% CO2.
Synthesis of pegylated gold nanoparticles
AuNPs were synthesized by the Turkevitch method [33, 34] . Briefly tetrachloroauric acid (HAuCl4) was reduced with trisodium citrate. HAuCl4 aqueous solution was heated to slight boiling and stirred. Trisodium citrate was added and boiled for 15 min. Then, AuNPs were pegylated (PEGAuNPs) with thiolated poly(ethylene glycol) layer (PEG) capped with a carboxylate group with a molar ratio 1:1,000, respectively.
The mixture was stirred at room temperature for about 1 h. The resultant solution was centrifuged at 13,400 × rpm (12,000 × g) during 10 min to remove the unbound PEG molecules. The concentration of the PEGAuNPs was 14.02 nM as determined by the Lambert-Beer Law assuming the molar absorptivity of the AuNPs plasmon resonance band at 526 nm being 2.
.
Conjugation of afatinib to PEGAuNPs
To prepare the afatinib conjugated to pegylated gold nanoparticles, we used EDC/NHSS coupling that can bind covalently with carboxyl groups of PEGAuNPs and amine groups of afatinib. The molar ratio PEGAuNPs:afatinib is 1:1540. The solution was stirred at room temperature for 1 h. The final solution was centrifuged at 13,400 rpm during 10 min to remove the unbound antitumour drug.
Dynamic light scattering and electrophoretic mobility measurements
Size distribution and zeta potential of the nanoparticles was analyzed by dynamic light scattering (DLS) and laser Doppler velocimetry, respectively, by a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK), at 25 ºC. Size measurements were performed at a scattering angle of 173 in a 12 mm square polystyrene cuvette (Sarstedt, Germany). The zeta potential was obtained by using a disposable capillary cell (DTS 1060, Malvern).
UV-VIS spectroscopy
The UV-VIS absorption spectra of the PEGAuNPs and PEGAuNPs-afatinib were measured in a 1 cm quartz cuvette at room temperature using a Shimadzu UV-1700 PharmaSpec spectrophotometer.
Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR)
The PEGAuNPs-afatinib, PEGAuNPs and afatinib solutions were analysed and ATR-FTIR spectra were recorded with an ALPHA FTIR Spectrometer (Bruker) in the spectral range 4,000-400 cm −1 , resolution of 4 cm −1 and 64 scans, at room temperature.
Assay of Protein Tyrosine Kinase
Afatinib activity was studied with Tyrosine Kinase Assay as described in the Universal Tyrosine Kinase assay kit (TAKARA). This kit enables the analysis of the regulation of PTK activity. It was measured the Protein Tyrosine Kinase (PTK) activity in a specific range of concentrations of 0.5 to 15 µM by its absorbance at 450 nm using a microplate reader (PowerWave HT Microplate Spectrophotometer, BioTek), in order to determine the afatinib calibration curve. To determine the encapsulation efficiency of afatinib from PEGAuNPs, it was measured the PTK activity of the supernatant after conjugation of afatinib with PEGAuNPs.
In vitro drug release studies
The drug release study of PEGAuNPs-afatinib was carried out at 37ºC by dialysis using a regenerated cellulose membrane with an initial afatinib concentration of 4.1 µM. The solutions were incubated in 6 mL of PBS 0.01 M, with constant magnetic stirring. It was obtained a significant afatinib concentration into PEGAuNPs and, then, the afatinib concentration of the dialysate buffer could be analyzed, with time, using spectrophotometric analysis at 247 nm (the concentration is under the limit of detection of the Shimadzu UV-1700 PharmaSpec spectrophotometer).
Cellular imaging studies
Imaging experiments were performed with the S2-013 and A549 cells. About 800 cells per well were grown for 24 h in a μ-chamber 12-well plates (ibidi, Germany) under normal conditions (5% CO2 humidified atmosphere at 37 ºC). The cells were incubated with 1.0 nM of PEGAuNPs for 2 hours. Following the incubation, the cells were rinsed with 1% of phosphate buffered saline (PBS) and fixed using 4% paraformaldehyde for 15 min. The cells were washed with PBS and mounted in a glycerol-based non-drying and non-hardening medium. Imaging was performed using a laser scanning confocal microscope (LSCM) TCS SP5 II (Leica Microsystems, Germany). To evaluate the nanoparticle internalization in the cells, the control untreated cells were also imaged. Different areas were analyzed and at least three images were acquired for each type of cell.
Flow cytometer assays
For cell cycle distribution analysis, samples were seeded with 1x10 5 cells in 1 mL and grown for 72 hours.
Conjugated nanoparticles were prepared freshly under sterile conditions. After incubation with nanoparticles and afatinib alone, cells were washed, pelleted, and resuspended in PBS (pH 7.4). Cells were then stained with DNA-binding dye propidium iodide (PI) immediately before flow cytometry (FACS Calibur, BD Biosciences, San Jose, CA, USA). Three independent experiments were carried out, including untreated controls. Flow cytometer assays were performed plotting at least 15,000 events per sample and data were subsequently analyzed by FlowJo 10.0.7 software (Tree Star, Ashland, USA. Alterations to the normal cell cycle profile after samples exposure was studied by total DNA staining.
Evaluation of in vitro cytotoxicity
The effects of the nanoparticles and drug on cell growth were evaluated by the Sulforhodamine B (SRB) assay (colorimetric) as previously described [9] .
Briefly, S2-013 and A549 cells were seeded in 96-well plates ( The SRB absorbance was measured at 560 nm using the PowerWave microplate reader. The concentration that inhibits cell survival in 50% (IC50) and the concentration that inhibits cell growth in 50% (GI50) were determined using the SRB assay. The absorbance of the wells containing the nanoparticles or drug and the absorbance of the wells containing untreated cells following a 72 h incubation period were subsequently compared with that of the wells containing the cells that had been fixed at time zero (when the nanoparticles and drug were added).
Statistical analysis
At least three independent experiments were performed for each assay. Statistical significance (p < 0.05) was determined by the Student's t-Test.
Results and Discussion
The citrate-stabilized AuNPs (pH of 5.1) were prepared and functionalized covalently with a hydrophilic polymer polyethylene glycol as a spacer. The average hydrodynamic diameter of PEGAuNPs (pH of 5.3) measured by DLS is 41 ±1 nm with a low polydispersity index, indicating uniform nanoparticles (Table 1 ). NPs present high stability as shown by -39 mV of zeta potential. Also, PEGAuNPs are stable for at least 6 months at 4 ºC and in the dark. The covalently linked bioconjugates of PEGAuNPs and afatinib (PEGAuNPs-afatinib)
were prepared through the coupling reaction of EDC/NHSS [35] . EDC reacted with the carboxylate groups forming an active ester (o-acylisourea) leaving group [35] . Then, from the reaction of the hydroxyl group on sulfo-NHS with EDC active-ester complex, a highly reactive sulfo-NHS-ester complex intermediate was formed [35] . The NHS-terminated AuNPs were mixed with afatinib solution, the side chains amino groups of the afatinib displaced the terminal NHS groups of PEGAuNPs. PEGAuNPs-afatinib obtained through covalent bounds do not significantly change their size and zeta potential changed to -35 mV (Table 1 ). Figure 1 shows the UV-vis spectra of NPs. The surface plasmon resonance (SPR) of PEGAuNPs is around 522 nm in water, typical of AuNPs, and their estimated concentration, determined by the Lambert-Beer Law, was 14.02 nM [15, 36] . In the presence of afatinib, it is possible to visualize the afatinib peaks at 247 and 341 nm.
In order to confirm the covalent bonds, we conducted the FTIR analysis of NPs. Figure 2 shows the ATR-FTIR spectra of modified PEGAuNPs. The distinct peaks of PEGAuNPs appeared at 1742 cm -1 from carbonyl groups of terminal carboxylic acid. A strong absorption band was observed at 1080 cm -1 , representing the C-O stretching of the ethylene glycol monomers [17] . The absence of representative peaks of S-H group (in the 2500-2600 cm -1 region, data not shown) indicates the fact that PEG layer is attached to AuNPs via Au-S bond.
For PEGAuNPs-afatinib, it displays the mainly characteristic peaks at 1640 cm -1 due to the reaction of secondary amine into a stable imide (C=N) linkage [37] . Thus, the characterization indicates the formation of stable and well-dispersed PEGAuNPs-afatinib.
The afatinib conjugation efficiency was confirmed through the Protein Tyrosine Kinase Assay and determined to be 26 ± 2% (by subtracting the unbound afatinib in the supernatant solution). Therefore, the final concentration of afatinib conjugated with PEGAuNPs was determined to be 3.6 ± 0.6 µM.
The in vitro controlled release experiment of afatinib alone and afatinib conjugated with PEGAuNPs were investigated, as shown in Figure 3 . The assay was performed through dialysis using a regenerated cellulose membrane with an initial afatinib concentration of 4.1 µM, in PBS 0.01 nM at 37 ºC for 72 hours. By comparing the release profiles of afatinib, a higher release from afatinib alone was detected when compared with the afatinib release from the PEGAuNPs-afatinib conjugates (Figure 3 ). It was observed that 60% of the amount of afatinib was released after 6 hours compared to only 15% of afatinib release for PEGAuNPsAfatinib ( Figure 3 ). After 27 hours, the amount of afatinib released from PEGAuNPs is 20%, in contrast to almost all of afatinib being released when in its free form (Figure 3 ). The amount of afatinib released from
PEGAuNPs after 72 hours of incubation remains constant and can occur due to the low bond-dissociation energy for removing successive sulphur atoms from gold nanoparticles (data not shown).
These results are in accordance with the fact that EDC/NHSS coupled reaction is highly efficient [35] . The sulfo-NHS-ester complex intermediate reacted, creating a stable imine linkage with the amine nucleophile secondary (afatinib) and, therefore, linkages do not readily break down, justifying the observed slow release of afatinib from conjugated PEGAuNPs [37] .
LSCM technique was used to image the pancreatic (S2-013) and NSCLC cancer cells (A549) incubated with
PEGAuNPs. Figure 4 shows the transmission image of the cancer cells that were incubated with PEGAuNPs for 2 hours. After the period of incubation with 1 nM PEGAuNPs, the internalization of NPs was detected ( Figure 4 ) and a higher contrast signal is detected in treated cancer cells compared with untreated cells (control). According to Silvia et al., nanoparticles are internalized by cancer cells even after a few minutes of incubation [9] . This fact is observed by an increase of the reflectance and transmission signal from cancer cells incubated with PEGAuNPs compared to the control cells. Also, an accumulation of the PEGAuNPs is observed in endocytic vesicles at the cell cytoplasm [9] .
In order to evaluate the potential contribution of conjugated PEGAuNPs with afatinib to cytotoxicity, pancreatic S2-013 and NSCLC A549 cells, both with overexpression of EGFR, HER2 and HER3 [38, 39] The pancreatic cancer cell line used, S2-013, is more resistant to both PEGAuNPs-afatinib and afatinib alone, when compared to the A549 cells. Cell growth was significantly inhibited, when afatinib is conjugated with
PEGAuNPs and for concentrations ranging from 0.132 to 0.369 µM.
The concentrations of afatinib alone inhibiting cell survival in 50% (IC50 values) were determined to be 0.50 ± 0.02 and 0.87 ± 0.04 µM for S2-013 and A549s, respectively (Table 3 ). Comparing the IC50 of afatinib alone and PEGAuNPs-afatinib it is possible to observe significant changes. Results indicate that 5 times more afatinib alone is necessary to inhibit S2-013 cell survival in 50% than PEGAuNPs-afatinib (IC50 of 0.50 ± 0.02 and 0.103 ± 0.001, respectively). Regarding the A549 cells, a concentration almost 20 times higher of afatinib alone is required than PEGAuNPs-afatinib to induce the same degree of cell survival inhibition (IC50 of 0.87 ± 0.04 and 0.044 ± 0.001, respectively), as seen in Figure 5 and Table 3 .
The same trend is observed when analyzing inhibition of cell growth in response to afatinib alone and PEGAuNPs-afatinib. For the S2-013s, the GI50 concentration lower for the PEGAuNPs-afatinib than that for afatinib alone (0.09 ± 0.01 and 0.30 ± 0.05 µM, respectively). Regarding A549 cells, the efficacy of PEGAuNPs-afatinib to inhibit cell growth is, also, more pronounced than that of afatinib alone (0.039 ± 0.001 and 0.75 ± 0.02 µM, respectively. Therefore, both cell survival (IC50) and cell growth inhibition (GI50) results
indicate that PEGAuNPs-afatinib is approximately 5 and 20 times more potent than afatinib alone in S2-013
and A549 cells, respectively, corroborating our hypothesis that the afatinib effect is enhanced by the cellular uptake of afatinib conjugated with PEGAuNPs. As mentioned above, these experiments were performed using cell lines that overexpress several ErbB family members, particularly of EGFR and HER2 and, to a lesser extent, HER3 [38, 39] . In addition to this, it may be interesting to investigate how the cell growth inhibition effect of the afatinib conjugated with PEGAuNPs would be observed in other cell lines with a range of different expression levels of the ErbB family members.
Conclusions
In summary, this work reports the preparation of afatinib-conjugated functionalized gold nanoparticles for Future work will be needed to clarify the uptake mechanisms of PEGAuNPs-afatinib. 
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